Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Not yet recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Gastrointestinal 1

Conditions

Thrombocytosis 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Hepatitis B, Chronic 1Hepatitis B 1Carcinoma, Hepatocellular 1

Interventions

Specimen Handling 57Magnetic Resonance Spectroscopy 39Carboplatin 32Cyclophosphamide 29Gemcitabine 28Bevacizumab 24pembrolizumab 23Cisplatin 23Biopsy 23Paclitaxel 22Standard of Care 21Radiotherapy 21Drug Therapy 21fludarabine 20Injections 20Capecitabine 20venetoclax 19Oxaliplatin 19Nivolumab 18Interviews as Topic 17toripalimab 16Dexamethasone 16Blood Specimen Collection 16Radiosurgery 14tislelizumab 13cemiplimab 13anlotinib 13Azacitidine 13Pemetrexed 12Irinotecan 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × peginterferon alfa-2b × 90 days × Clear all
NCT07468916 2026-05-06

Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia

Jonsson Comprehensive Cancer Center

Phase 2 Not yet recruiting
35 enrolled
MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Thrombocytosis, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT07553767 2026-04-28

Efficacy and Safety of Pegylated Interferon Alpha-2β in Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical Resection

Ningbo No.2 Hospital

Phase EARLY_PHASE1 Not yet recruiting
156 enrolled
Gastrointestinal

Hepatitis B, Carcinoma, Hepatocellular, Hepatitis B, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡